Skip to main content

Advertisement

SpringerLink
Log in

Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study

  • Clinical Investigation
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Background

Radioembolization induced liver disease (REILD) is a possible sequela of transarterial radioembolization (TARE), particularly in cases of whole-liver treatment. To mitigate this problem, the safety and efficacy of combined transarterial chemoembolization (TACE) and TARE were evaluated for patients with bilobar hepatocellular carcinoma (HCC).

Materials and Methods

Nineteen patients (mean age 60 years; range 27–82 years) treated for HCC between June 2012 and September 2014 were included in the analysis. Each patient was treated with combined TARE and TACE for bilobar HCC, with or without portal vein thrombosis. The hepatic lobe with large HCC was treated with TARE, and the other lobe with small HCC(s) was treated with TACE. Laboratory and clinical data were investigated to determine REILD occurrence. Survival data were analyzed to compare the treatment efficacy of alternative treatment modalities, including TACE and sequential TARE.

Results

All patients underwent TARE for a dominant tumor in one lobe and TACE for small nodule(s) in the other lobe of the liver. The mean yttrium-90 microspheres used in TARE were 2.8 GBq (range; 1.0-3.5 GBq), and the mean doses of doxorubicin and iodized oil were 24.5 mg and 5.2 mL, respectively, for TACE. No statistical differences were noted between laboratory data measured before and after treatment, and no procedure-related major clinical complications occurred. The median time-to-progression of patients was 10.0 months, and the median overall survival was 27.3 months.

Conclusion

Combined radioembolization and chemoembolization appears to be a safe and effective treatment modality for bilobar HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.

    Article  CAS  PubMed  Google Scholar 

  3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55.

    Article  PubMed  Google Scholar 

  4. Sangro B. Chemoembolization and radioembolization. Best Pract Res Clin Gastroenterol. 2014;28(5):909–19.

    Article  CAS  PubMed  Google Scholar 

  5. Di Marco V, De Vita F, Koskinas J, et al. Sorafenib: from literature to clinical practice. Ann Oncol. 2013;24(Suppl 2):ii30–7.

    Article  PubMed  Google Scholar 

  6. Cho YY, Lee M, Kim HC, et al. Radioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLoS ONE. 2016;11(5):e0154986.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rostambeigi N, Dekarske AS, Austin EE, et al. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2014;25(7):1075–84.

    Article  PubMed  Google Scholar 

  8. Lobo L, Yakoub D, Picado O, et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2016;39(11):1580–8.

    Article  PubMed  Google Scholar 

  9. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013;57(3):1078–87.

    Article  CAS  PubMed  Google Scholar 

  10. Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112(7):1538–46.

    Article  PubMed  Google Scholar 

  11. Denys A, Pracht M, Duran R, et al. How to prepare a patient for transarterial radioembolization? A practical guide. Cardiovasc Intervent Radiol. 2015;38(4):794–805.

    Article  PubMed  Google Scholar 

  12. Piana PM, Gonsalves CF, Sato T, et al. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol. 2011;22(10):1373–9.

    Article  PubMed  Google Scholar 

  13. Kao YH, Tan EH, Ng CE, et al. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med. 2011;25(7):455–61.

    Article  PubMed  Google Scholar 

  14. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006;17(10):1571–93.

    Article  PubMed  Google Scholar 

  15. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38.

    Article  CAS  PubMed  Google Scholar 

  16. Kim DY, Ryu HJ, Choi JY, et al. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35(11):1343–50.

    Article  CAS  PubMed  Google Scholar 

  17. El Fouly A, Ertle J, El Dorry A, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int. 2015;35(2):627–35.

    Article  PubMed  Google Scholar 

  18. Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11(6):604–11 (quiz e43–4).

    Article  PubMed  PubMed Central  Google Scholar 

  19. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303–10.

    Article  PubMed  Google Scholar 

  20. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47(1):71–81.

    Article  PubMed  Google Scholar 

  21. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009;20(9):1121–30 (quiz 1131).

    Article  PubMed  Google Scholar 

  22. Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74(5):1494–500.

    Article  CAS  PubMed  Google Scholar 

  23. Ward TJ, Tamrazi A, Lam MG, et al. Management of high hepatopulmonary shunting in patients undergoing hepatic radioembolization. J Vasc Interv Radiol. 2015;26(12):1751–60.

    Article  PubMed  Google Scholar 

  24. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33(4):919–24.

    Article  CAS  PubMed  Google Scholar 

  25. Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24(3):293–8.

    CAS  PubMed  Google Scholar 

  26. Bester L, Salem R. Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. J Vasc Interv Radiol. 2007;18(10):1310–4.

    Article  PubMed  Google Scholar 

  27. Moreno-Luna LE, Yang JD, Sanchez W, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36(3):714–23.

    Article  PubMed  Google Scholar 

  28. Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715–21.

    Article  PubMed  Google Scholar 

  29. Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21(2):224–30.

    Article  PubMed  Google Scholar 

  30. Carr BI, Kondragunta V, Buch SC, et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116(5):1305–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497–507 (e2).

    Article  PubMed  Google Scholar 

  32. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741–9.

    Article  CAS  PubMed  Google Scholar 

  33. Bhangoo MS, Karnani DR, Hein PN, et al. Radioembolization with yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol. 2015;6(5):469–78.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea

    Joon Ho Kwon, Gyoung Min Kim, Kichang Han, Jong Yun Won, Man Deuk Kim, Do Yun Lee, Junhyung Lee, Woosun Choi & Yong Seek Kim

  2. Department of Internal Medicine, Institution of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea

    Do Young Kim & Kwang-Hyub Han

  3. Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea

    Gyoung Min Kim

Authors
  1. Joon Ho Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gyoung Min Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kichang Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jong Yun Won
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Man Deuk Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Do Yun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Junhyung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Woosun Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yong Seek Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Do Young Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kwang-Hyub Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gyoung Min Kim.

Ethics declarations

Conflict of interest

The authors have no conflicts to report.

Ethical Approval

For this type of study formal consent is not required.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kwon, J.H., Kim, G.M., Han, K. et al. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. Cardiovasc Intervent Radiol 41, 459–465 (2018). https://doi.org/10.1007/s00270-017-1826-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-017-1826-7

Keywords

Search

Navigation